LOS ANGELES, CA, United States, via ETELIGIS INC., 11/09/2012 - - Cell Therapeutics Inc (NASDAQ: CTIC) shares increased 4.17% to $1.25. The company reported third quarter total operating expenses were $14.7 million compared to $15.3 million for the same period in 2011. Net loss was $20.2 million ($0.38 per share) for the quarter ended September 30, 2012 compared to a net loss attributable to common shareholders of $29.7 million ($0.80 per share) for the same period in 2011.
Will CTIC Move Higher After Today’s Sudden Selling Activities? Don’t Miss The Free Trend Analysis here http://beststocksdaily.com/p2/index.php?company=CTIC
Molycorp Inc (NYSE: MCP) shares fell 7.83% to $8.01 in the early hour after the company posted a third quarter net loss of $15.5 million, or 19 cents a share, versus net income of $45.1 million, or 49 cents a share, in the same quarter a year earlier. Adjusted net loss was 5 cents a share, smaller than the adjusted loss that analysts had expected of 7 cents a share. Revenue for the third quarter came in at $205.6 million, up 49%, boosted in part by its Neo Materials acquisition.
How Should Investors Trade MCP After The Recent Momentum, Find Out Here http://beststocksdaily.com/p2/index.php?company=MCP
PVR Partners LP (NYSE: PVR) shares decreased 2.67% to $23.35 after the company’s public offering of 6.5 million common units priced at a 3.7% discount to Thursday's close. Units were recently trading 5.6% lower at $22.65 premarket, compared with the offering's price of $23.11 a unit. The company said it was offering the common units to raise funds for the repayment of debt.
Get Free Special Trend Analysis On PVR Here http://beststocksdaily.com/p2/index.php?company=PVR
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) shares declined 23.91% to $4.02 after the company posted reported that revenues increased by 9% for the quarter ended September 30, 2012, to $40.7 million, compared to revenues for the same period in the prior year of $37.4 million. GAAP net loss for the third quarter of 2012 was $13.5 million, compared with net income of $10.2 million for the same period in the prior year, or a net loss of $0.24 per share on both a basic and diluted basis for the three months ended September 30, 2012, compared with a net gain of $0.18 and $0.17 per share on a basic and diluted basis, respectively, for the same period in the prior year.
Get Free Special Trend Analysis On SCLN Here http://beststocksdaily.com/p2/index.php?company=SCLN
Array Biopharma Inc (NASDAQ: ARRY) shares fell 11.70% to $3.59 after the company announced the pricing of an underwritten public offering of 18,000,000 primary shares of its common stock at a public offering price of $3.65 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $65.7 million. The offering is expected to close on or about November 15, 2012, subject to customary closing conditions.
Get Free Special Trend Analysis On ARRY Here http://beststocksdaily.com/p2/index.php?company=ARRY
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, Hot Stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
1419 Westwood Blvd Los Angeles, CA